• 四川大學(xué)華西醫(yī)院神經(jīng)內(nèi)科,成都,610041;

通過TRIP和SUM search,檢索MEDLINE和Cochrane圖書館,獲得治療晚期帕金森病長期美多巴治療后合并開-關(guān)現(xiàn)象、異動癥以及伴抑郁的證椐,并對這些證據(jù)進(jìn)行了評價.據(jù)所獲證據(jù),結(jié)合醫(yī)生的經(jīng)驗及病人的愿望制定了循證治療方案,患者癥狀得到明顯緩解.

引用本文： 彭蓉,何俐. 晚期帕金森病的循證治療. 中國循證醫(yī)學(xué)雜志, 2004, 04(3): 210-211. doi: 復(fù)制

1. ［1］Hughes AH, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’ s disease: a clinicopathological study of 100 cases [ J ]. J Neurol Neurosurg Psychiatry, 1992; 55: 181-184.
2. ［2］Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality [J]. Neurology, 1967; 17(5): 427-442.
3. ［3］Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H,Stem M, Shoulson 1, Kurlan R, Gtitnes JD, Jankovic J, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease [J].Mov Disord, 1994; 9(1): 40-47.
4. ［4］Lieberman A, Imke S, Muenter M, Wheeler K, Ahlskog JE,Matsumoto JY, Maraganore DM, Wright KF, Schoenfelder J.Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson’ s disease patients with fluctuating responses to levodopa/carbidopa [J]. Neurology, 1993; 43(10):1981-1984.
5. ［5］inter MM, Pogarell O, Oertel WH, et al. Efficacy safety, and tolerance of the non-ergoline dopamine agonist pramipexole inthe treatment of advanced Parkinson’ s disease: a double blind,placebo controlled, randomised, multicentre study [ J ]. J Neurol Neurosurg Psychiatry, 1999; 66(4): 436-41.
6. ［6］Ziegler M. Efficacy ofpiribedil in adjunction to L-dopa in a 6 month randomized placebo controlled study in early Parkinson’s disease [J ]. Neurology Aeurology. 2000; 54 ( Suppl 3 ).
7. ［7］Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease [J ]. International Pramipexole-Bromocriptine Study Group. Neurology, 1997; 49(4): 1060-1065.
8. ［8］Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F.The SSRI, citalopram, improves bradykinesia in patients with Parkinson’s disease treated with L-dopa [ J ]. Clin Neuropharmacol, 2002; 25 ( 1 ): 21-24.
9. ［9］Serrano-Duenas M. A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson’ s disease [J].Rev Neurol, 2002; 35( 11 ): 1010-1014.
10. ［10］Tesei S, AntoniniA, Canesi M, Zecchinelli A, Mariani CB,Pezzoli G. Tolerability of paroxetine in Parkinson’s disease: a prospective study [J]. Mov Disord, 2000; 15(5): 986-989.
11. ［11］Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease [J ]. Mov Disord, 1997; 12(5): 756-759.
  1. 1. ［1］Hughes AH, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’ s disease: a clinicopathological study of 100 cases [ J ]. J Neurol Neurosurg Psychiatry, 1992; 55: 181-184.
  2. 2. ［2］Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality [J]. Neurology, 1967; 17(5): 427-442.
  3. 3. ［3］Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H,Stem M, Shoulson 1, Kurlan R, Gtitnes JD, Jankovic J, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease [J].Mov Disord, 1994; 9(1): 40-47.
  4. 4. ［4］Lieberman A, Imke S, Muenter M, Wheeler K, Ahlskog JE,Matsumoto JY, Maraganore DM, Wright KF, Schoenfelder J.Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson’ s disease patients with fluctuating responses to levodopa/carbidopa [J]. Neurology, 1993; 43(10):1981-1984.
  5. 5. ［5］inter MM, Pogarell O, Oertel WH, et al. Efficacy safety, and tolerance of the non-ergoline dopamine agonist pramipexole inthe treatment of advanced Parkinson’ s disease: a double blind,placebo controlled, randomised, multicentre study [ J ]. J Neurol Neurosurg Psychiatry, 1999; 66(4): 436-41.
  6. 6. ［6］Ziegler M. Efficacy ofpiribedil in adjunction to L-dopa in a 6 month randomized placebo controlled study in early Parkinson’s disease [J ]. Neurology Aeurology. 2000; 54 ( Suppl 3 ).
  7. 7. ［7］Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease [J ]. International Pramipexole-Bromocriptine Study Group. Neurology, 1997; 49(4): 1060-1065.
  8. 8. ［8］Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F.The SSRI, citalopram, improves bradykinesia in patients with Parkinson’s disease treated with L-dopa [ J ]. Clin Neuropharmacol, 2002; 25 ( 1 ): 21-24.
  9. 9. ［9］Serrano-Duenas M. A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson’ s disease [J].Rev Neurol, 2002; 35( 11 ): 1010-1014.
  10. 10. ［10］Tesei S, AntoniniA, Canesi M, Zecchinelli A, Mariani CB,Pezzoli G. Tolerability of paroxetine in Parkinson’s disease: a prospective study [J]. Mov Disord, 2000; 15(5): 986-989.
  11. 11. ［11］Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease [J ]. Mov Disord, 1997; 12(5): 756-759.